Comparison of hepatic resection and systemic treatment of breast cancer liver metastases: A propensity score matching study

Feng, Yun; Zhou, Changming; Zhang, Qiongyan; Huang, Shengyu; Zheng, Li; Zhang, Yongfa; Pan, Qi; Ji, Yuan; Zheng, Ying; Shao, Zhimin; Wang, Lu

doi:10.1016/j.amjsurg.2020.02.047

Cited by 16 publications

(18 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In turn, these patients exhibited better prognoses not because of the surgical treatment but because of their more indolent biology. This may explain the disparate results of some studies in this meta-analysis: the Sadot et al's study (26) which found comparable 5-year OS in surgically vs. systemically treated patients with BCLM, and the studies of Feng et al and Ruiz et al (22,25) which found that surgically resected patients had improved OS compared to those treated with systemic therapy. Indeed, in the latter two studies, the surgical groups had up to 100% proportions of patients who had stable disease control after adequate systemic therapy.…”

Section: Discussionmentioning

confidence: 81%

“…Some studies managed to balance the baseline characteristics to overcome selection bias by paired design or propensity score matching. Of the nine studies included, three were unmatched studies (20,21,24), another six were matched studies (22,23,(25)(26)(27)(28), with four of which reporting the comparing outcomes before matching (22,23,25,26). Finally, seven unmatched cohorts and six matched cohorts were included in the pooled analysis.…”

Section: Combined Results Of the Matched/unmatched Cohortsmentioning

confidence: 99%

“…unilobar distributed lesions, normal liver function, and good performance statuses (8)(9)(10)29). These unique characteristics might represent the selective criteria of surgical treatment for patients with isolated BCLM in clinical practice (22,28). They represented an early or intermediate state in the progression of BCLM when potential cure may be easily achieved by multidisciplinary treatment.…”

Section: Discussionmentioning

confidence: 99%

“…After deduplicating titles and screening abstracts, 28 full-texts were reviewed, of which further 19 studies were excluded for various reasons (Figure 1). Ultimately, nine studies (20)(21)(22)(23)(24)(25)(26)(27)(28) were included in this meta-analysis. Characteristics of included studies, matching covariates, and study quality evaluated using (23) included patients with non-osseous extrahepatic metastases in the surgical cohort, which accounted for 9.6%, but no patients in the systemic cohort had any non-osseous extrahepatic metastases.…”

Section: Study Characteristicsmentioning

confidence: 99%

See 3 more Smart Citations

Survival Benefit of Surgical Treatment Added Into Systemic Treatment for Isolated Breast Cancer Liver Metastases: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Background: Compared with systemic treatment alone, whether surgical treatment combined with systemic treatment can improve survival outcomes of patients with isolated breast cancer liver metastases (BCLM) is still controversial. This meta-analysis was designed to evaluate the efficacy of surgical treatment for patients with isolated BCLM.Methods: A systematic search of PubMed, Embase, and Cochrane Library up to May 13, 2021 was conducted for relevant studies. The primary outcome was overall survival. The meta-analysis was performed using R software. The quality of the pooled study was assessed using the Newcastle-Ottawa scale. The publication bias was evaluated by funnel plots and Begg's and Egger's tests. Fixed- and random-effects models were applied according to heterogeneity.Results: 9 retrospective studies involving 13 cohorts (7 unmatched cohorts and 6 matched cohorts) were included in this study. The surgical cohorts had better overall survival than the systemic cohorts in the pooled analysis of all the included studies, in the subgroup analysis of liver resection, and in the subset of the matched cohorts.Conclusions: Compared with systemic treatment alone, surgical treatment combined with systemic treatment was proven to be associated with superior survival outcomes, which should be considered in selected patients with isolated BCLM.

show abstract

Section: Discussionmentioning

confidence: 81%

Section: Combined Results Of the Matched/unmatched Cohortsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

See 2 more Smart Citations

Survival Benefit of Surgical Treatment Added Into Systemic Treatment for Isolated Breast Cancer Liver Metastases: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Most studies summarize a broad variety of cancer entities with differing prognosis to groups. Only for breast cancer (Feng et al 2020), kidney cancer (Bauschke et al 2021;Ruys et al 2011), gastric cancer (Luo et al 2019), and sarcoma (Grimme et al 2019) exist a small number of studies with adequate sample size to help clinicians to make a decision for or against surgical therapy.…”

Section: Introductionmentioning

confidence: 99%

Surgical treatment of liver metastases from non-colorectal non-neuroendocrine carcinomas

Bauschke

Altendorf-Hofmann

Homman

et al. 2021

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Introduction In the literature, results after surgical treatment of non-colorectal non-neuroendocrine liver metastases (NCNNLM) are reported that are often inferior to those from colorectal liver metastases. The selection of patients with favorable tumor biology is currently still a matter of discussion. Materials/methods The retrospective data analysis was based on data that were collected for the multicenter study “Role of surgical treatment for non-colorectal liver metastases” in county Thuringia. Results For the study, 637 patients were included from 1995 to 2018. 5 and 10-year survival of R0 resected patients were 33% and 19%, respectively. In the multi-variate analysis of the entire group, sex, timing, disease-free interval, number of metastases, R-classification as well as lymph node status of the primary lesion showed an independent statistical influence on the 5-year survival. In the group of R0 resected patients, disease-free interval, number of metastases and lymph node status of the primary lesion influenced the 5-year survival in the multi-variate analysis. In kidney malignancies, R-classification, timing and number of liver metastases were statistically significant in the multi-variate analysis of the 5-year survival, in mamma carcinomas only the R-classification. Conclusion The Adam score identifies some risk factors which influence prognosis in most but not in all tumor entities. For kidney cancer and breast cancer it can be simplified.

show abstract

Potential molecular mechanisms and clinical progress in liver metastasis of breast cancer

Liu

et al. 2022

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Comparison of hepatic resection and systemic treatment of breast cancer liver metastases: A propensity score matching study

Cited by 16 publications

References 28 publications

Survival Benefit of Surgical Treatment Added Into Systemic Treatment for Isolated Breast Cancer Liver Metastases: A Systematic Review and Meta-Analysis

Survival Benefit of Surgical Treatment Added Into Systemic Treatment for Isolated Breast Cancer Liver Metastases: A Systematic Review and Meta-Analysis

Surgical treatment of liver metastases from non-colorectal non-neuroendocrine carcinomas

Potential molecular mechanisms and clinical progress in liver metastasis of breast cancer

Contact Info

Product

Resources

About